Comparison of Telomerase Activity and Matrix Metalloproteinase-9 in Voided Urine and Bladder Wash Samples as a Useful Diagnostic Tool for Bladder Cancer

Eissa, Sanaa; Labib, Randa; Mourad, Sherif; Kamel, Khaled Mahmoud; el-Ahmady, O

doi:10.1016/s0302-2838(03)00417-2

Cited by 29 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A portion of the pellet was used for cytological and microscopical examinations. The remaining part was treated with 500 lL of protease inhibitor cocktail [14] and stored at -80°C for further processing to extract DNA.…”

Section: Collection Of Samplesmentioning

confidence: 99%

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence

et al. 2009

Self Cite

View full text Add to dashboard Cite

Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity. The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer. This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological disorders and 47 healthy volunteers. The urine supernatant was used for determination of fibronectin by ELISA, while urine sediment was used for cytology and detection of mutant p53 by PCR-SSCP followed by DNA sequencing. The sensitivity and specificity were 59% and 91.4% for VUC, 82% and 84.3% for fibronectin, and 37% and 100% for mutant p53; combination of the three parameters increased sensitivity to 95% but specificity was only 78.6%. A significant association was observed between disease recurrence and mutant p53, stage and lymph node involvement. Our results indicate that fibronectin had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, mutant p53 had superior specificity compared to VUC and fibronectin. Mutant p53 is associated with disease recurrence and hence it has a significant prognostic role in bladder cancer.

show abstract

Section: Collection Of Samplesmentioning

confidence: 99%

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additional studies were excluded as they were not case-control or cohort studies (n=19), were irrelevant to the present study (n=4) or possessed incomplete data (n=1). Overall, 23 case-control studies (15,(18)(19)(20)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47), published between 1998 and 2014, were selected for meta-analysis, and consisted of 1,040 bladder cancer patients and 244 healthy control individuals. Among the 23 studies, the study subjects in 3 studies were African, 14 studies enrolled Asian subjects and 6 studies enrolled Caucasian subjects.…”

Section: Resultsmentioning

confidence: 99%

Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer

Zeng

Cen²,

Kang³

2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study investigated the potential association between matrix metalloproteinase-9 (MMP-9) expression and the pathogenesis of bladder cancer. The present study reviewed previous studies published in Chinese and English using predefined selection criteria, which identified high-quality studies concerning MMP-9 and bladder cancer. Statistical analyses of the data were conducted using Comprehensive Meta-Analysis software version 2.0. In total, 23 case-control studies were selected, which consisted of 1,040 bladder cancer patients and 244 healthy controls. The expression rates and protein levels of MMP-9 were significantly increased in bladder cancer patients compared with the healthy controls, which was demonstrated using immunohistochemistry (IHC) and enzyme-linked immunosorbent assay-based methods. Furthermore, the expression rate of MMP-9 in histological G1/G2 grade bladder cancer tumors was significantly decreased compared with G3 tumors. Subgroup analysis based on ethnicity demonstrated that the rate of MMP-9 protein expression between bladder cancer patients and healthy controls was significantly different in African, Asian and Caucasian patients, which was identified using IHC. The MMP-9 protein levels in bladder cancer patients and healthy controls were significantly different between Asian and Caucasian patients, but not African patients. The differences between MMP-9 expression in ethnic groups were also evident in the expression rate of MMP-9 identified in histological G1/G2 grade tumors in Asian and Caucasian patients compared with G3 grade tumors, which was not evident in African patients. In conclusion, the present meta-analysis results markedly indicate that MMP-9 expression is associated with clinicopathological features of bladder cancer, suggesting that MMP-9 may be a useful biomarker in the diagnosis and clinical management of bladder cancer, and may be a valuable therapeutic target. IntroductionWorldwide, bladder cancer is the 7th most common cancer in men and the 17th most common cancer in women (1). Notably, in the developed world, bladder cancer ranks as the 4th and 9th most common cancer in men and women, respectively (2). An estimated 375,000 bladder cancer cases are reported each year around the world, with 68,810 novel cases and ~14,100 mortalities reported in the United States in 2013 (3). Transitional cell carcinoma is the most frequently occurring type of bladder cancer. Other bladder cancer types consist of adenocarcinoma, squamous cell carcinoma and small cell bladder cancer (4,5). Notably, the incidence of bladder cancer increases with age, particularly in men (6). Bladder cancer arises as a result of multistep alterations, among which metastasis is crucial (7). Epidemiological studies have demonstrated that several environmental factors may contribute to bladder cancer risk, including smoking, chronic inflammation, radiation exposure, anticancer drugs and aromatic amines, which are contained in dyes (6,8). The treatment of bladder cancer is based on multiple para...

show abstract

“…However, there was potential publication bias in the quantitative analysis of p16 deletion and p27. The association of telomerase by TERT [31][32][33]57] or TRAP [31][32][33]58,59], sFas [8,32,34], CD44 [37,[60][61][62], and RARb2 [46,63,64] with schistosomal bladder cancer is shown in Fig. 4.…”

Section: Comparison Between Schistosomal and Non-schistosomal Bladdermentioning

confidence: 98%

Molecular markers and Schistosoma-associated bladder carcinoma: A systematic review and meta-analysis

Koonrungsesomboon

Wadagni²,

Mbanefo

2015

Cancer Epidemiology

View full text Add to dashboard Cite

Comparison of Telomerase Activity and Matrix Metalloproteinase-9 in Voided Urine and Bladder Wash Samples as a Useful Diagnostic Tool for Bladder Cancer

Cited by 29 publications

References 24 publications

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence

Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer

Molecular markers and Schistosoma-associated bladder carcinoma: A systematic review and meta-analysis

Contact Info

Product

Resources

About